Publications by authors named "I Dogliotti"
Background: Despite the adoption of pediatric-like chemotherapy protocols, the introduction of new immunotherapies and a better understanding of the oncogenic landscape, the outcome for adult patients with acute lymphoblastic leukemia (ALL) remain substantially dismal. The aim of the present study was to evaluate the outcome in terms of survival in a cohort of adult patients with ALL who received allogeneic hematopoietic stem cell transplantation (alloSCT) between 2013 and 2023.
Methods: This was a single-center observational retrospective study including all consecutive adult patients with ALL who received an alloSCT between April 2013 and April 2023 at the Stem Cell Transplant Center AOU Città della Salute e della Scienza of Torino.
Article Synopsis
- Researchers studied how a treatment called Azacitidine-donor lymphocyte infusion (AZA/DLI) works for patients who had a relapse of a serious blood disease after a transplant.
- They found that 41.4% of patients responded well to the treatment, and the time they stayed healthy varied, with some doing really well and others not as much.
- The results showed that certain gene levels (WT1) and disease risk factors affected how long patients lived after the treatment, helping doctors understand who might need extra help.
Background: Relapse and refractory (R/R) rates after first-line R-CHOP in diffuse large B cell lymphomas (DLBCL) are ~40% and ~15% respectively.
Aims: We conducted a retrospective real-world analysis aimed at evaluating clinical outcomes of R/R DLBCL patients.
Material And Methods: Overall, 403 consecutive DLBCL patients treated in two large hematological centers in Torino, Italy were reviewed.
Novelty in total body irradiation (TBI) as part of pre-transplant conditioning regimens lacked until recently, despite the developments in the field of allogeneic stem cell transplants. Long-term toxicities have been one of the major concerns associated with TBI in this setting, although the impact of TBI is not so easy to discriminate from that of chemotherapy, especially in the adult population. More recently, lower-intensity TBI and different approaches to irradiation (namely, total marrow irradiation, TMI, and total marrow and lymphoid irradiation, TMLI) were implemented to keep the benefits of irradiation and limit potential harm.
View Article and Find Full Text PDFArticle Synopsis
- * In a retrospective analysis of 226 patients from 2008 to 2021, the study found a cumulative incidence of 29.9% for acute GVHD and 29.8% for chronic GVHD, along with 1, 2, and 3-year non-relapse mortality rates of 18.2%, 19.6%, and 20.2%, respectively.